ATE550023T1 - Stabile feste zubereitung mit 4,5- epoxymorphinanderivat - Google Patents

Stabile feste zubereitung mit 4,5- epoxymorphinanderivat

Info

Publication number
ATE550023T1
ATE550023T1 AT08752145T AT08752145T ATE550023T1 AT E550023 T1 ATE550023 T1 AT E550023T1 AT 08752145 T AT08752145 T AT 08752145T AT 08752145 T AT08752145 T AT 08752145T AT E550023 T1 ATE550023 T1 AT E550023T1
Authority
AT
Austria
Prior art keywords
solid preparation
stable solid
derivative
epoxymorphinand
effective ingredient
Prior art date
Application number
AT08752145T
Other languages
English (en)
Inventor
Suguru Takaki
Kotoe Ohta
Yasuhide Horiuchi
Masato Kobayashi
Junko Kawasaki
Eijiro Horisawa
Original Assignee
Toray Industries
Maruho Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Maruho Kk filed Critical Toray Industries
Application granted granted Critical
Publication of ATE550023T1 publication Critical patent/ATE550023T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Epoxy Resins (AREA)
AT08752145T 2007-04-26 2008-04-25 Stabile feste zubereitung mit 4,5- epoxymorphinanderivat ATE550023T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007116721 2007-04-26
PCT/JP2008/058111 WO2008133330A1 (ja) 2007-04-26 2008-04-25 4,5-エポキシモルヒナン誘導体を含有する安定な固形製剤

Publications (1)

Publication Number Publication Date
ATE550023T1 true ATE550023T1 (de) 2012-04-15

Family

ID=39925776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08752145T ATE550023T1 (de) 2007-04-26 2008-04-25 Stabile feste zubereitung mit 4,5- epoxymorphinanderivat

Country Status (14)

Country Link
US (1) US8420662B2 (de)
EP (1) EP2151241B1 (de)
JP (2) JP5099127B2 (de)
KR (1) KR101491656B1 (de)
CN (1) CN101686976B (de)
AT (1) ATE550023T1 (de)
AU (1) AU2008244936B2 (de)
CA (1) CA2685131C (de)
DK (1) DK2151241T3 (de)
ES (1) ES2381056T3 (de)
MX (1) MX2009011554A (de)
PL (1) PL2151241T3 (de)
PT (1) PT2151241E (de)
WO (1) WO2008133330A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
WO2012054566A2 (en) * 2010-10-19 2012-04-26 Memorial Sloan-Kettering Cancer Center 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
JP2013087170A (ja) * 2011-10-17 2013-05-13 Nippon Soda Co Ltd ヒドロキシプロピルセルロース微粒子
DK2851075T3 (da) 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
GB201318394D0 (en) * 2013-10-17 2013-12-04 Univ Edinburgh Composition
EP4212532A3 (de) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynin-analoga und verwendungen davon
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
US11185509B2 (en) 2016-07-29 2021-11-30 Toray Industries, Inc. Solid preparation having improved light stability
ES2902123T3 (es) * 2017-03-31 2022-03-25 Toray Industries Composición medicinal en tabletas que comprende nalfurafina
DK3761982T3 (da) 2018-03-08 2025-01-02 Victoria Link Ltd Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme
WO2020205735A1 (en) * 2019-03-29 2020-10-08 Humanwell Pharmaceutical US Novel morphinans useful for treating medical disorders
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
EP4212149A1 (de) * 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Orale dosierungsformen von säurelabilen salzen und verfahren und verwendung davon

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
DE69732868T2 (de) * 1996-11-25 2006-04-13 Toray Industries, Inc. Mittel gegen Juckreiz
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
JP4939680B2 (ja) 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
PT948965E (pt) * 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
US6524568B2 (en) * 1998-06-22 2003-02-25 Cytomedix, Inc. Enriched platelet wound healant
DE60110666T2 (de) * 2000-03-17 2006-02-02 Shin-Etsu Chemical Co., Ltd. Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren
JP3698652B2 (ja) 2000-03-17 2005-09-21 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法
AU2001248751A1 (en) 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
JP3595765B2 (ja) * 2000-09-27 2004-12-02 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤
WO2002070013A1 (en) 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Utilization of spray-dried powder containing sugar alcohol
KR20040098660A (ko) 2002-03-14 2004-11-20 유로-셀티크 소시에떼 아노뉨 날트렉손 하이드로클로라이드 조성물
US20050208127A1 (en) * 2002-06-10 2005-09-22 Kazuyoshi Ogasawara Rapidly disintegrating tablet and process for producing the same
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone

Also Published As

Publication number Publication date
KR101491656B1 (ko) 2015-02-09
PT2151241E (pt) 2012-05-07
WO2008133330A1 (ja) 2008-11-06
US20100120815A1 (en) 2010-05-13
ES2381056T3 (es) 2012-05-22
JP5099127B2 (ja) 2012-12-12
JP2012180382A (ja) 2012-09-20
PL2151241T3 (pl) 2012-08-31
JP5578199B2 (ja) 2014-08-27
JPWO2008133330A1 (ja) 2010-07-29
CN101686976A (zh) 2010-03-31
CA2685131A1 (en) 2008-11-06
CN101686976B (zh) 2013-04-24
CA2685131C (en) 2015-05-19
KR20100015582A (ko) 2010-02-12
DK2151241T3 (da) 2012-04-23
EP2151241A1 (de) 2010-02-10
AU2008244936A1 (en) 2008-11-06
AU2008244936B2 (en) 2013-02-21
EP2151241A4 (de) 2010-06-02
US8420662B2 (en) 2013-04-16
MX2009011554A (es) 2010-01-25
EP2151241B1 (de) 2012-03-21

Similar Documents

Publication Publication Date Title
ATE550023T1 (de) Stabile feste zubereitung mit 4,5- epoxymorphinanderivat
MA32604B1 (fr) Composes organiques
EA200900044A1 (ru) Замещенные производные 1,3-дифенилпропана, получение и их применение
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
UY28797A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparación y el uso de las mismas para combatir hongos nocivos, así como productos que las contienen.
CO6280584A2 (es) Derivados heterociclicos fungicidas de (tetrazolil-benzilideneamido)-oximetil
MX2011011175A (es) Coposiciones herbicidas de alta concentracion de las sales de glifosato y de 2,4-d.
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
JP2015514120A5 (de)
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
EP2153831A4 (de) Antiermüdungsmittel und orale zusammensetzung, beide mit andrographolid als wirkstoff
EA201300715A1 (ru) Бульонный кубик
BRPI0922701A8 (pt) Método para intensificar atividade viral mediada por interferon em um animal de companhia
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
CO6351744A2 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridini-3-il]-2-metil-4´-(trifluoro-metoxi)-[1,1´-bifenil]-3-carboxamida
TN2010000585A1 (en) Pharmaceutical compositions of rosuvastatin calcium
BRPI0814549A2 (pt) Composição antimicrobiana
CY1116266T1 (el) Σταθερα αλατα της s-αδενοσυλμεθειονινης και μεθοδος παρασκευης τους
MX2012006265A (es) Formulaciones disacaridas hipersulfatadas.
PT2146683E (pt) Utilização de um extrato aquoso de sementes de uva em associação com pelo menos um sal de flúor contra a formação ou acumulação de biofilme dentário e composições compreendendo essa associação
BR112012014564A2 (pt) "método de combate e controle de pragas"
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives